Treatment of the Acute Humoral Rejection in Kidney Allografts

Introduction: Acute humoral rejection (AHR) is a severe complication for renal transplantation usually causing a poor graft prognosis. A recent therapeutic approach with plasmapheresis and intravenous immunoglobulins (IVIg) has being proposed. Purpose: To describe the effectiveness of the treatment...

Full description

Bibliographic Details
Authors: Ribeiro, Adriana Reginato, Berdichevski, Roberto Herz, Silva, Daniel Melquíades da, Mazzali, Marilda, Gonçalves, Luiz Felipe dos Santos, Manfro, Roberto Ceratti
Format: article
Status:Published version
Publication Date:2009
Country:Brasil
Institution:Associação Brasileira de Transplante de Órgãos (ABTO)
Repository:Brazilian Journal of Transplantation
Language:Portuguese
OAI Identifier:oai:ojs3.emnuvens.com.br:article/259
Online Access:https://bjt.emnuvens.com.br/revista/article/view/259
Access Level:Open access
Keyword:Transplante de Rim
Rejeição de Enxerto
Plasmaferese
Imunoglobinas
Soro Antilinfocitário
Muromonab-CD3
Renal Transplantation
Graft Rejection
Plasmapheresis
Intravenous Immunoglobulins
Antilynphocyte Serum
Renal transplantation, Graft Rejection, Plasmapheresis, Intravenous Immunoglobulins, Antilynphocyte Serum, Muromonab-CD3
Description
Summary:Introduction: Acute humoral rejection (AHR) is a severe complication for renal transplantation usually causing a poor graft prognosis. A recent therapeutic approach with plasmapheresis and intravenous immunoglobulins (IVIg) has being proposed. Purpose: To describe the effectiveness of the treatment of AHR. Patients and methods: From January 2002 to April 2008 fifteen patients were diagnosed as having AHR, and they were treated with plasmapheresis and IVIg or ATG/OKT3 in our institution. Results: Reversal of AHR was attained in twelve (80%) patients. One-year patient and graft survivals were 100% and 73%, respectively. One successfully treated patient had the immunosuppressive regimen discontinued due the presence of sepsis, and the graft was subsequently lost. Conclusion: We concluded that this is an efficient therapeutic, allowing the survival of the majority of grafts.

Similar Items